Patent Application
20190367886
The present invention relates to a method for producing a vaccinia virus expressing a foreign gene and use of the obtained vaccinia virus.
Currently, preclinical and clinical studies on cancer therapies using live viruses have been actively conducted worldwide. The cancer virus therapy is a method utilizing inherent nature of viruses, which is to kill infected cells and tissues by growing and propagating therein. Such a method, compared to the conventional radiation therapy and chemotherapy, exhibits anticancer effects via diverse mechanisms by firstly oncolysis due to virus growth, and secondly induction of antitumor immunity associated therewith.
There are vaccine strains of a vaccinia virus which were established in Japan some time ago and have been used in human as a smallpox vaccine and thereby proven to be highly safe (see Non Patent Literature 1). However, the strains still retain attenuated growth potential in normal tissues, and thus the modification for growing only in cancer cells was needed to be established as a safer cancer virus therapy. Thus, the modification was made based on these vaccine strains by gene recombination technique, and a gene recombinant vaccinia virus growing in and damaging specifically cancer cells was successfully developed, using control dysfunction of the MAPK/ERK pathway in a wide range of cancers as the indicator (see Patent Literatures 1 and 2).
The present invention has an object to provide a method for producing a vaccinia virus expressing a foreign gene and the vaccinia virus.
Vaccinia virus can be used as a cancer therapeutic virus by introducing a therapeutic gene as a foreign gene, and can also be used as a vaccine by introducing an antigen of a bacterium and the like as a foreign gene, and thereby a number of applications are conceivable. For these applications, a foreign gene needs to be introduced into the vaccinia virus, and the present inventors extensively conducted studies on methods for easily and quickly introducing a foreign gene to the vaccinia virus.
The present inventors first inserted a marker gene such as a fluorescent marker gene into an endogenous gene or an untranslated region of a vaccinia virus, and subsequently replaced the fluorescent marker gene with a foreign gene of interest to be introduced by homologous recombination. In the case of introducing a gene into a cell or a microorganism, the introduction of the gene is not easily confirmed, whereas in the case of inserting a marker gene first and subsequently replacing the marker gene with a foreign gene of interest, the introduction of the foreign gene can be confirmed using a loss of a signal such as fluorescence caused by the marker gene as an indicator, enabling easy, definite, and quick introduction of the foreign gene.
The present inventors inserted a fluorescent protein gene in advance to an endogenous VGF gene and an O1L gene of a vaccinia virus to prepare a vaccinia virus mitogen-activated protein kinase (MAPK)-dependent recombinant vaccinia virus (MD-RVV) being deprived of the VGF gene and the O1L gene and having an anticancer action (International Publication No. WO2015/076422). Suicide genes (CD gene and UPRT gene) were introduced by the above method to the vaccinia virus wherein the fluorescent protein gene was inserted into the endogenous gene. Such a vaccinia virus being deprived of the functions of the VGF gene and the O1L gene and further having the suicide genes inserted is confirmed to be capable of killing cancer cells by not only the effect of MD-RVV but also the effect of the suicide genes.
The present invention is as follows.
The present description includes the disclosed contents of JP Patent Application No. 2016-138712, which is the basis of the priority of the present application.
A foreign gene of interest can be easily, definitely, and quickly introduced into a vaccinia virus when a marker gene such as a fluorescent marker gene is first inserted into an endogenous gene or an untranslated region of the vaccinia virus, and subsequently the fluorescent marker gene is replaced with the foreign gene of interest to be introduced by homologous recombination. Further, the vaccinia virus wherein a suicide gene prepared by this method is introduced can kill cancer cells by not only the cancer cell killing effect provided by the vaccinia virus but also the action of the suicide gene.
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
Hereinafter, the present invention is described in detail.
The present invention relates to a method for preparing a vaccinia virus expressing a foreign gene and a vaccinia virus expressing the obtained specific foreign gene.
For the vaccinia virus expressing a foreign gene of the present invention, a marker gene is first inserted into an endogenous gene or an untranslated region of a vaccinia virus.
Subsequently, the inserted marker gene is replaced with a foreign gene of interest to be inserted into the vaccinia virus.
At the time, the replacement of the marker gene with the foreign gene of interest is confirmed using the signal caused by the expression product of the marker gene as an indicator. More specifically, when the marker gene is replaced with the foreign gene, the signal from the expression product of the marker gene is lost, whereby the replacement of the marker gene with the foreign gene can be determined using the loss of the signal as the indicator. For example, in the case where the marker gene is a fluorescent protein gene, the replacement of the marker gene with the foreign gene can be determined using the existence of the fluorescence emitted by the fluorescent protein as the indicator.
The vaccinia virus expressing a foreign gene of the present invention can also be prepared by using a vaccinia virus having a marker gene inserted into an endogenous gene or an untranslated region originally present therein. The vaccinia virus having a marker gene inserted into an endogenous gene originally present therein refers to, for example, a vaccinia virus having a marker gene inserted into an endogenous gene for the purpose of causing loss of the function of a specific endogenous gene.
The endogenous gene into which a marker gene is first inserted is not limited, but a gene which is not required for the life cycle of the vaccinia virus is preferable. Alternatively, a marker gene can be inserted into a gene for which even when loss of the function occurs by insertion of a marker gene, the loss can be compensated in cancer cells by abundant enzymes of cancer cells, but the loss of the function cannot be compensated in normal cells and the like.
Examples of the endogenous gene include vaccinia virus growth factor (VGF) gene (U.S. Patent Application No. 2003/0031681 Description); O1L gene; hemagglutinin (HA) gene; thymidine kinase (TK) gene; F fragment; F3 gene; bleeding region or A-type inclusion body region (U.S. Pat. No. 6,596,279 Description); Hind III F, F13L or Hind III M region (U.S. Pat. No. 6,548,068 Description); A33R, A34R or A36R gene (Katz et al., J. Virology 77: 12266-12275 (2003)); SalF7L gene (Moore et al., EMBO J. 1992 11:1973-1980); N1L gene (Kotwal et al., Virology 1989 171:579-58); M1 gene (Child et al., Virology. 1990 174:625-629); HR, HindIII-MK, HindIII-MKF, HindIII-CNM, RR or BamF region (Lee et al., J Virol. 1992 66:2617-2630); and C21L gene (Isaacs et al., Proc Natl Acad Sci U S A. 1992 89:628-632). Of these genes, VGF gene, O1L gene, TK gene, HA gene, and F fragment are preferable.
A marker gene may be inserted into one or more, for example, 1 or 2, or 1 to 3, of these endogenous genes.
For example, lacking the function of the TK by inserting a marker gene into the TK gene of the vaccinia virus means that the TK gene is not expressed or, even if expressed, the expressed protein does not retain the normal TK function. When the function of the TK gene is lost, the growth ability of the vaccinia virus in normal cells declines. On the other hand, the growth ability in cancer cells does not decline because there are abundant enzymes compensating this gene function present in cancer cells. The declined growth ability in normal cells means that the pathogenicity against normal cells declines, more specifically, the safety is improved when applied to a living body.
Further, lacking the functions of the VGF and O1L genes by inserting a marker gene into VGF and O1L genes of the vaccinia virus means that the gene encoding VGF and the gene encoding O1L are not expressed or, even if expressed, the expressed protein does not retain the normal functions of VGF and O1L. As an example of the endogenous gene, the gene sequences of VGF and O1L of the vaccinia virus are presented respectively as set forth in SEQ ID NOS: 10 and 11. When the vaccinia virus being deprived of the functions of VGF and O1L infects normal cells, ERK is not activated in normal cells and thus the cell growth is not promoted, resulting in the notable decline of vaccinia virus growth. On the other hand, the Ras/Raf/MEK/ERK metabolic pathway abnormally activated in cancer cells compensates the activation function of ERK by VGF and O1L, of the vaccinia virus, whereby the vaccinia virus can grow. As a result, the vaccinia virus grows specifically in cancer cells and damages the cancer cells causing destruction. More specifically, the mitogen-activated protein kinase-dependent recombinant vaccinia virus of the present invention has the cancer cell-specific oncolytic effect.
The untranslated region refers to regions which are present on both sides of the coding region of mRNA and not translated to a protein, and includes the 5′ untranslated region and the 3′ untranslated region. The untranslated region of the present invention includes both of the untranslated regions.
The marker gene to be inserted into the endogenous gene or the untranslated region described above is also called a reporter gene and examples include fluorescent protein genes such as luciferase (LUC) gene and green fluorescent protein (GFP), fluorescent protein genes such as red fluorescent protein (DsRed), β glucuronidase (GUS) gene, chloramphenicol acetyltransferase (CAT) gene, and β-galactosidase (LacZ) gene.
The insertion of a marker gene into the endogenous gene or the untranslated region may be carried out by, for example, homologous recombination. Homologous recombination is a phenomenon in which two DNA molecules are mutually recombined via the same nucleotide sequence in a cell and is the method often used for recombining viruses having an enormous genetic DNA such as the vaccinia virus. First, a plasmid to which a marker gene is connected (this is called “transfer vector”) is constructed in the form of splitting at the center of the DNA sequence of the endogenous gene site or the untranslated region of the vaccinia virus to be targeted and introduced into cells infected with the vaccinia virus, whereby the recombination is caused between the virus DNA which becomes naked in the process of the virus replication and the same sequence part on the transfer vector, thereby integrating the interposed marker gene into the virus genome. For the cell to be used herein, a vaccinia virus-infectable cell such as CV1 cell, RK13 cell, BSC-1 cell, HTK-143 cell, Hep2 cell, MDCK cell, Vero cell, HeLa cell, COS cell, BHK-21 cell, or primary rabbit kidney cell can be used. Additionally, the introduction of the vector to a cell may be carried out by a well-known method such as calcium phosphate method, cationic liposome method, or electroporation method.
For example,
Further, when the marker gene is introduced, it is desirable to operably link a suitable promoter upstream of the marker gene. The promoter is not limited but PSFJ1-10, PSFJ2-16, p7.5 K promoter, p11K promoter, T7.10 promoter, CPX promoter, HF promoter, H6 promoter, T7 hybrid promoter, or the like can be used. The method for introducing the marker gene to the vaccinia virus vector of the present invention can be carried out by a well-known method for constructing a recombinant vaccinia virus vector by following, for example, the description in Experimental Medicine Supplement, The protocol series, Gene transfer & Experimental method of analyzing expression, edited by Izumi Saito et al., YODOSHA CO., LTD. (published Sep. 1, 1997) or D. M. Glover et al. edition, supervised by Ikunoshin Kato, DNA Cloning 4-Mammalian Systems-(2nd edition) TaKaRa, EMBO Journal, 1987, vol. 6, p. 3379-3384.
The vaccinia viruses having marker genes inserted in the endogenous genes originally found therein are described, for example, in International Publication No. WO2011/125469 and International Publication No. WO2015/076422, and can be prepared by following the methods described in these publications. International Publication No. WO2011/125469 describes the vaccinia virus having marker genes inserted into the endogenous genes, TK gene, HA gene, and so on and having the functions of TK and HA lost. Additionally, International Publication No. WO2015/076422 describes the vaccinia virus having marker genes inserted into the VGF (vaccinia virus growth factor) gene and the O1L gene and having the functions of VGF (vaccinia virus growth factor) and O1L, lost. This vaccinia virus is called the mitogen-activated protein kinase (MAPK)-dependent recombinant vaccinia virus (MD-RVV).
The vaccinia virus strain for producing the vaccinia virus having a marker gene inserted into the endogenous gene originally found therein is not limited, and examples include stains such as Lister strain, LC16 strain, LC16mO strain, and LC16m8 strain established from Lister strain (So Hashizume, Clinical Virology, vol.3, No.3, 269, 1975, etc.), and NYBH strain, Wyeth strain, Copenhagen strain, WR strain, and MVA strain. LC16mO strain is the strain generated from Lister strain via LC16 strain, and LC16m8 strain is further generated from LC16mO strain and attenuated strain because the B5R gene encoding a viral membrane protein had a frameshift mutation and thereby the protein was not expressed or did not function (PROTEIN, NUCLEIC ACID AND ENZYME, Vol.48 No. 12 (2003), p. 1693-1700).
The vaccinia virus having a marker gene inserted into the endogenous gene originally found therein used in the present invention is preferably attenuated and not pathogenic. Examples of the attenuated strain include strains having the B5R gene partially or completely deleted. The B5R gene encodes the protein present in the envelope of vaccinia virus and the B5R gene product is involved with the infection and growth of the virus. The B5R gene product is present on the infected cell surface and in the envelope of the virus, works to increase the efficiency when the virus infects and propagates in adjacent cells or other parts of the host body, and is also involved with the plaque size and the range of host. When the virus having the B5R gene deleted is caused to infect animal cells, the plaque size reduces and the pock size also reduces. Additionally, the growth ability on the skin declines, and the pathogenicity to the skin declines. For the vaccinia virus having the B5R gene partially or completely deleted, the B5R gene product fails to function normally, has the reduced skin growth ability, and does not cause adverse reaction when administered to human. Examples of the attenuated strain with the B5R gene deleted include m8Δ strain established by completely deleting the B5R gene, for example, from the above LC16m8 strain (also called LC16m8Δ strain). Additionally, mOΔ strain established by completely deleting the B5R gene from LC16mO strain (also called LCmOΔ strain) can also be used. These attenuated vaccinia virus strains having the B5R gene partially or completely deleted are described in International Publication No. WO2005/054451 and can be obtained by following the description therein. Whether or not the vaccinia virus has the B5R gene partially or completely deleted and the function of the B5R protein is lost can be determined, for example, by the size of plaque and the size of pock formed when infected with RK13 cells, the virus growth properties in vero cells, and the pathogenicity to the skin in rabbit as indicators. Alternatively, the gene sequence of vaccinia virus may also be investigated.
The vaccinia virus expressing a foreign gene of the present invention, when used for a cancer therapy, is designed in such a way as to express the B5R gene in cancer cells and cause the damage of the cancer cells by the action of the B5R protein. In this case, it is desirable that the vaccinia virus to be used express the complete B5R gene. When the vaccinia virus which does not have the B5R gene and is attenuated and established the safety as described above is used, a new complete B5R gene is newly introduced into the vaccinia virus having the B5R gene deleted. When the vaccinia virus having B5R gene partially or completely deleted is used, a B5R gene is inserted into such a vaccinia virus genome and may be used as a material for the vaccinia virus production of the present invention. The insertion of the B5R gene into the vaccinia virus may be carried out by any method and may be carried out by, for example, a known homologous recombination method. Further, the position at which the B5R gene is inserted in this case may be between the B4R gene and the B6R gene where the B5R gene was originally present, or at any site in the genome of the vaccinia virus. Further, the B5R gene may be constructed as a DNA construct in advance and introduced into the vaccinia virus.
Examples of the foreign gene (foreign DNA or foreign polynucleotide) with which the marker gene is replaced include therapeutic genes encoding products having the cytotoxicity and immunostimulatory effect, and further DNA encoding a protein antigen of a cancer, a virus, a bacterium, a protozoan, or the like. Further examples include suicide genes such as cytosine deaminase (CD) gene, uracil phosphoribosyltransferase (UPRT) gene, herpes simplex virus thymidine kinase (HSV-tk) gene, guanine phosphoribosyltransferase (gpt) gene, and nitroreductase gene.
All of the marker genes inserted into the endogenous gene may be replaced with foreign genes, or one or more of the marker genes, for example, 1 or 2, or 1 to 3 marker genes, may be replaced with foreign genes.
The therapeutic gene is the gene used for treating specific diseases such cancers and infectious diseases and examples include tumor suppressor genes such as p53 and Rb; genes encoding a physiologically active substance such as interleukin 1 (IL-1), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, α-interferon, β-interferon, γ-interferon, angiostatin, thrombospondin, endostatin, METH-1, METH-2, GM-CSF, G-CSF, M-CSF, or a tumor necrosis factor; and genes encoding sodium iodide symporter (NIS). The gene encoding sodium iodide symporter (NIS) may be used in combination with a radioactive iodine, thereby enabling the delivery of a radioactive isotope to tumor tissues. When the vaccinia virus expressing a foreign gene of the present invention is used for a cancer therapy, a therapeutic gene against a cancer, together with the oncolysis provided by the vaccinia virus, can demonstrate cancer therapeutic effects.
Further, when DNA encoding an antigen of a virus, a bacterium, a protozoan, a cancer, or the like is introduced as a foreign gene (foreign DNA), the vaccinia virus vector into which the foreign gene is introduced can be used as the vaccine against various viruses, bacteria, protozoans, and cancers. For example, an infection protective antigen (neutralizing antigen) such as human immunodeficiency virus, hepatitis virus, herpes virus, micobacterium, malaria plasmodium, severe acute respiratory syndrome (SARS) virus, or a gene encoding a cancer antigen may be introduced.
These foreign genes can be introduced by, for example, using the technique of homologous recombination. The homologous recombination may be carried out by the method described above. For example, a plasmid (transfer vector) into which a foreign gene to be introduced is linked to a DNA sequence at an introduction site is prepared, which may be introduced into a cell infected with the vaccinia virus. The introduction region for the foreign gene is preferably a gene which is not required for the life cycle of the vaccinia virus. Alternatively, in cancer cells, the foreign gene may also be inserted, for example, into a gene for which, even when the function is lost by the insertion of the gene, the lost function can be compensated by abundant enzymes found in cancer cells but not compensated in normal cells.
Further, when the foreign gene is introduced, it is desirable to operably link a suitable promoter upstream of the foreign gene. The promoter is not limited but PSFJ1-10, PSFJ2-16, p7.5 K promoter, p11K promoter, T7.10 promoter, CPX promoter, HF promoter, H6 promoter, T7 hybrid promoter, or the like, described above can be used. The method for introducing the foreign gene to the vaccinia virus vector of the present invention can be carried out by a well-known method for constructing a recombinant vaccinia virus vector by following, for example, the description in Experimental Medicine Supplement, The protocol series, Gene transfer & Experimental method of analyzing expression, edited by Izumi Saito et al., YODOSHA CO., LTD. (published Sep. 1, 1997) or D. M. Glover et al. edition, supervised by Ikunoshin Kato, DNA Cloning 4 -Mammalian Systems-(2nd edition) TaKaRa, EMBO Journal, 1987, vol. 6, p. 3379-3384, and so on.
When the vaccinia virus is used for a cancer therapy, the cancer to be targeted is not limited and various cancer types, when classified by the cancer-causing organ, are targeted, such as lung cancer, pancreatic cancer, ovarian cancer, skin cancer, stomach cancer, liver cancer, colorectal cancer, colon cancer, anal-rectal cancer, esophagus cancer, uterine cancer, breast cancer, bladder cancer, prostate cancer, esophagus cancer, brain—nerve tumors, lymphoma, leukemia, bone-bone sarcoma, leiomyoma, and rhabdomyoma.
The pharmaceutical composition for cancer therapy comprising the vaccinia virus of the present invention comprises a pharmaceutically effective amount of the vaccinia virus of the present invention as an effective ingredient and may be in the form of a sterile aqueous or nonaqueous solution, suspension, or emulsion. Further, the composition may comprise a pharmaceutically acceptable diluent, aid, or carrier such as a salt, a buffer agent, and an adjuvant. The administration may be carried out via various parenteral routes such as subcutaneous route, intravenous route, intradermal route, intramuscular route, intraperitoneal route, intranasal route, or transdermal route. Additionally, local administration may be carried out to a cancer site. The effective dose can be suitably determined by the age, sex, health conditions, and body weight of a subject. For example, the dose is, but not limited thereto, about 102 to 1010 plaque-forming unit (PFU) per administration to a human adult.
For example, when the CD gene, which is a suicide gene, is used as the foreign gene, 5-fluorocytosine (5-FC) is administered to a subject together with the vaccinia virus capable of expressing the CD gene. Cytosine deaminase (CD), which is an expression product of the CD gene, converts 5-FC to 5-fluorouracil (5-FU), which is a cytotoxic anticancer agent, whereby the anticancer effect is demonstrated. Further, when the UPRT gene, which is a suicide gene, is used as the foreign gene, 5-fluorouracil (5-FU) is administered to a subject together with the vaccinia virus capable of expressing the UPRT gene. Uracil phosphoribosyltransferase (UPRT), which is an expression product of the UPRT gene, enhances the anticancer effect of 5-FU.
Both CD gene and UPRT gene may be used as the foreign genes, and in this case, 5-FC is administered to a subject together with the vaccinia virus capable of expressing the CD gene and the UPRT gene. 5-FC is converted to 5-FU by cytosine deaminase (CD), which is an expression product of the CD gene, and the anticancer agent effect is further enhanced by uracil phosphoribosyltransferase (UPRT), which is an expression product of the UPRT gene.
Further, when the herpes simplex virus thymidine kinase (HSV-tk) gene, which is a suicide gene, is used as the foreign gene, ganciclovir (GCV), aciclovir, penciclovir or the like is administered to a subject together with the vaccinia virus. GCV itself does not have a drug activity but is monophosphorylated by HS-tk and further converted to triphosphate in the cell. The triphosphorylated GCV attacks cancer cells infected with the vaccinia virus to kill the cancer cells.
Furthermore, when the guanine phosphoribosyltransferase (gpt) gene, which is a suicide gene, is used as the foreign gene, 6-thioxanthine or 6-thioguanine may be administered, and when the nitroreductase gene is used, CB1954 may be administered.
In the case where the vaccinia virus grows in normal cells and causes an adverse reaction, if a suicide gene is expressed in the vaccinia virus, the growth of the virus can be stopped by the action of the suicide gene and thereby the adverse reaction is suppressed.
The present invention encompasses vaccinia viruses comprising a suicide gene as a foreign gene and expressing the suicide gene. The suicide genes are preferably inserted into the vaccinia virus growth factor (VGF) gene and the O1L gene, and such a virus is deprived of functions of the vaccinia virus growth factor (VGF) gene and the O1L gene, and has oncolytic effect of not growing in normal cells but growing specifically in cancer cells, and destroying specifically the cancer cells, and further can kill the cancer cells by an action of the suicide gene.
Further, as illustrated in
Examples of the suicide gene include cytosine deaminase (CD) gene, uracil phosphoribosyltransferase (UPRT) gene, herpes simplex virus thymidine kinase (HSV-tk) gene, guanine phosphoribosyltransferase (gpt) gene and nitroreductase gene, and a fusion gene of a plurality of suicide genes may be inserted and examples include a fusion gene of the cytosine deaminase (CD) gene and the uracil phosphoribosyltransferase (UPRT) gene.
Examples of the vaccinia virus of the present invention include the vaccinia virus (VGF-EL-Fcy::Fur/O1L -EL-LacZ) wherein a fusion gene of the cytosine deaminase (CD) gene and the uracil phosphoribosyltransferase (UPRT) gene is inserted into the vaccinia virus growth factor (VGF) gene and further the β-galactosidase (LacZ) gene is inserted into the O1L gene.
The present invention encompasses a pharmaceutical composition for cancer therapy, more specifically, an anticancer agent, comprising such a vaccinia virus as an effective ingredient. The pharmaceutical composition can be used in combination with 5-fluorocytosine (5-FC) or 5-fluorouracil (5-FU). For example, when only the cytosine deaminase (CD) gene is, or the cytosine deaminase (CD) gene and the uracil phosphoribosyltransferase (UPRT) gene are, or the fusion gene thereof is inserted into the vaccinia virus, the composition may be used in combination with 5-fluorocytosine (5-FC), and when only the uracil phosphoribosyltransferase (UPRT) gene is inserted into the vaccinia virus, the composition may be used in combination with 5-fluorouracil (5-FU).
The present invention encompasses a combined formulation or a combination kit of the above vaccinia virus and 5-fluorocytosine (5-FC) or 5-fluorouracil (5-FU). Further, the present invention encompasses the pharmaceutical composition comprising the vaccinia virus as the effective ingredient and used in combination with 5-fluorocytosine (5-FC) or 5-fluorouracil (5-FU). The vaccinia virus and 5-fluorocytosine (5-FC) or 5-fluorouracil (5-FU) may be administered simultaneously or may be administered separately. Further, these ingredients may be sequentially administered, and the administration order may be the vaccinia virus being first or 5-fluorocytosine (5-FC) or 5-fluorouracil (5-FU) being first.
The present invention is described specifically in reference to the following Examples but is not limited to these Examples.
For easily and quickly inserting a foreign gene expression unit to the VGF gene or the O1L gene, a BFP gene region was first amplified using two primers (SEQ ID NO: 1 and SEQ ID NO: 2) using the DNA of pTagBFP-N (FP172, Evrogen) as a template. Each of the PCR products was cleaved with the restriction enzymes SfiI and EcoRI and cloned into the same restriction enzyme sites of the pTK-SP-LG vector (International Publication No. WO2015/076422) to construct pTK-SP-BFP wherein BFP is linked under the synthetic vaccinia virus promoter (Hammond J M. et al., Journal of Virological Methods. 1997; 66(1):135-138). Subsequently, the pTK-SP-BFP was cleaved with the restriction enzymes SphI and EcoRI, blunt treated, subsequently the SP-BFP fragment was cleaved and cloned into a site where the pUC19-VGF vector (International Publication No. WO2015/076422) was cleaved with a restriction enzyme Accl and blunt treated, or cloned into a site where the pUC19-O1L vector (International Publication No. WO2015/076422) was cleaved with a restriction enzyme Xbal and blunt treated, to construct a shuttle vector pTNshuttle/VGF-SP(EL)-BFP or pTNshuttle/O1L -SP(EL)-BFP.
For harvesting the recombinant vaccinia virus having the virus genome shown in
For inserting an expression unit of a foreign gene to the VGF gene, a yeast cytosine deaminase (CD)/uracil phosphoribosyltransferase (UPRT) fusion (Fcy::Fur) gene region was amplified using two primers (SEQ ID NO: 7 and SEQ ID NO: 8) using the plasmid DNA of pORF5-Fcy::Fur (InvivoGen) as a template. The PCR product thereof was cleaved with the restriction enzymes NheI and MluI and cloned into the same restriction enzyme sites of the pIRES vector (Clontech) to construct pIRES-Fcy::Fur. The Fcy::Fur obtained by cleaving the pIRES-Fcy::Fur with the restriction enzymes SfiI and SphI was cloned into the same restriction enzyme sites of the pTK-SP-BFP vector in such a way as to be replaced with the BFP gene, whereby pTK-SP-Fcy::Fur was constructed. On the other hand, the E. coli LacZ gene (SEQ ID NO: 9) synthesized in such a way as to be codon-optimized for H. sapiens was cleaved with the restriction enzymes AgeI and NheI and cloned into the same restriction enzyme sites of the pTNshuttle/VGF-SP(EL)-BFP vector in such a way as to be replaced with the BFP gene, whereby pTNshuttle/VGF-SP(EL)-LacZ was constructed. Subsequently, the Fcy::Fur fragment obtained by cleaving pTK-SP-Fcy::Fur with the restriction enzyme SphI, blunt treating, subsequently cleaving with AgeI was cloned into the vector fragment obtained by cleaving pTNshuttle/VGF-SP(EL)-BFP with NheI, blunt treating, and subsequently cleaving with AgeI, whereby pTNshuttle/VGF-SP(EL)-Fcy::Fur was constructed.
For inserting an expression unit of a foreign gene into the O1L, gene, the LucGFP fragment obtained by cleaving pIRES-LucGFP (International Publication No. WO2015/076422) with the restriction enzyme EcoRI, blunt treating, and subsequently cleaving with EcoRI was cloned into the vector fragment obtained by cleaving pTNshuttle/O1L-SP(EL)-BFP with the restriction enzymes AgeI and NheI and blunt treating, whereby pTNshuttle/O1L-SP(EL)-LucGFP was constructed. Additionally, the E. coli LacZ gene (SEQ ID NO: 9) synthesized in such a way as to be codon-optimized for H. sapiens was cleaved with the restriction enzymes AgeI and NheI and cloned into the same restriction enzyme sites of the pTNshuttle/O1L -SP(EL)-BFP vector in such a way as to be replaced with the BFP gene, whereby pTNshuttle/O1L-SP(EL)-LacZ was constructed.
For harvesting the recombinant vaccinia virus having the virus genome shown in
For harvesting the recombinant vaccinia virus having the virus genome shown in
As described above, the present rescue system can generate the recombinant vaccinia viruses expressing only 2 types of foreign genes of interest based on the platform for generating the gene recombinant vaccinia expressing 2 different types of fluorescent proteins (
For confirming the actual expression and function of the foreign genes introduced by the present rescue system, characterization of the generated recombinant vaccinia viruses was carried out. First, for confirming the expressions of the LucGFP and LacZ genes inserted into the O1L region, human pancreatic cancer Panc1 cells were inoculated at 6×103/well in a 96-well plate, cultured at 37° C. for 24 hours, and subsequently infected with LC16mO VGF-EL-Fcy::Fur/O1L -EL-LucGFP or LC16mO VGF-EL-Fcy::Fur/O1L -EL-LacZ at MOI=0, 0.01, 0.1 respectively (n=3), followed by, after 72 hours from the infection, observing the GFP fluorescence, quantifying the luciferase emission, X-Ga1 Staining, and measuring titers (
Furthermore, staining of the cells infected with LC16mO VGF-EL-Fcy::Fur/O1L -EL-LacZ was carried out using Genlatis X-Ga1 Staining Assay Kit (Genlantis Inc.) (
Additionally, when cell-associated virus was harvested from the Panc1 cells infected with the above LC16mO VGF-EL-Fcy::Fur/O1L -EL-LucGFP or LC16mO VGF-EL-Fcy::Fur/O1L -EL-LacZ by freezing and thawing, cell disrupting (sonicating) treatment, and centrifuging (2,000 rpm, 4° C., 10 min) and the titer was measured using the RK13 cells, both viruses were confirmed to have increased virus titers associated with the increase in the virus multiplicity of infection (
Finally, for analyzing the expression of the Fcy::Fur gene introduced into the VGF region, seven human pancreatic cancer cell lines (AsPC1·AsPC1 CD44v9 High: 7×103/well, BxPC3·Panc1·SW1990: 6×103/well, MiaPaca2: 5×103/well, and Panc10.05: 1×104/well), eight human ovarian cancer cell lines (A2780: 6×103/well, ES-2: 6×103/well, KF: 6×103/well, KFTx: 6×103/well, OVCAR3: 5×103/well, RMG-1: 6×103/well, SHIN-3: 6×103/well, and SKOV3: 6×103/well), four human colon cancer cell lines (Caco2, HT29, Lovo, and SW480 (all at 6×103/well)), two human breast cancer cell lines (MCF-7 and SK-BR-3 (all at 6×103/well)), and one human lung cancer cell line (A549: 6×103/well) were inoculated in a 96-well plate, cultured at 37° C. for 24 hours, and subsequently infected with three viruses, VGF-/O1L -(International Publication No. WO2015/076422) (LG/DsRed), LC16mO VGF-EL-Fcy::Fur/O1L -EL-LucGFP (FF/LG), or LC16mO VGF-EL-Fcy::Fur/O1L -EL-LacZ (FF/LacZ) at MOI=0.01, 0.1, 1 respectively (n=3). Then, after 48 hours from the infection, 5-FC was added at 0 μg/ml, 1 μg/ml, 10 μg/ml, 100 μg/ml, cultured at 37° C. for 72 hours, and subsequently measured for the cell viabilities using Promega Celltiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega Corporation) (
At MOI=1 where a virus multiplicity of infection is high, for many cell lines such as pancreatic cancers AsPC1 CD44v9 High, BxPC3, MiaPaca2, Panc10.05, Panc1, and SW1990, ovarian cancers ES-2, KF, KFTx, RMG-1, and SHIN-3, colon cancers Caco2 and SW480, breast cancers MCF-7 and SK-BR-3, and lung cancer A549 which are killed by the virus alone, enhanced cell death due to the addition of 5-FC was not found, whereas for pancreatic cancer AsPC1, ovarian cancers A2780, OVCAR3, and SKOV3, colon cancers HT-29 and Lovo, and so on in which the cell death is hardly caused by virus alone, the enhanced cell death depending on the amount of 5-FC added was confirmed (
For confirming the expression and function of the foreign gene introduced by the present rescue system in mice in vivo, studies were conducted to detect emission of the luciferase-introduced virus using xenotransplantation models, to examine combined use of 5-FC and the Fcy::Fur-introduced virus using allotransplantation models, and to examine antiviral therapeutic effects in both models.
In the xenotransplantation, six pancreatic cancer cell liness (AsPC1 CD44v9 High, BxPC3, Miapaca2, Panc1, Panc10.05, and SW1990) constantly expressing Renilla luciferase (R1uc) were intraperitoneally transplanted at 5×106 cells into the CB.17 ICR-SCID/SCID Jc1 mice, and allowed to engraft and grow for 1 to 2 weeks. LC16mO VGF-EL-Fcy::Fur/O1L -EL-LucGFP (FF-LG) was intraperitoneally administered at 1×106PFU to mice having peritoneally disseminated pancreatic cancer after transplantation to confirm the virus growth after administration and the expression of the foreign gene introduced into the virus, and observe the survival rate (
Observing the expression of the virus F1uc, intraperitoneal intense luciferase emission virus growth) was confirmed in all the virus administered mice (FF-LG) 2 days after virus administration, but the emission was attenuated 10 days after virus administration (
Further, in the allotransplantation, mouse colon cancer MC38 cells were subcutaneously transplanted at 1×105 cells to C57BL6Jjcl mice and allowed to grow for about 10 days until the tumor reached 44 to 95 mm3. After the tumor was grown, LC16mO VGF-EL-Fcy::Fur/O1L -EL-LacZ(FF/LacZ) was directly administered at 1×108 PFU into the tumor, and 1 day after, 12.5 mg of 5-FC was intraperitoneally administered to the mice. The alternate administration of the virus and 5-FC was carried out 6 times, and the antitumor effect and the combination effect with the prodrug of the virus were studied by subsequent tumor size measurement. As a result, the combination use of the virus and prodrug (FF-LacZ+5-FC) suppressed the growth of the tumor compared to the virus nonadministered mice (PBS+PBS, PBS+5-FC) and virus single-administered mice (FF-LacZ+PBS), and the two-way ANOVA analysis of variance confirmed that there was a significant difference (* P<0.05) compared to the tumor volume of the virus nonadministered mice (PBS+PBS) 15 days later and there was an extremely significant difference compared to the tumor volumes of the virus nonadministered mice and the virus single-administered mice 17 days later (*** P<0.001, ****P<0.0001) (
As stated above, the recombinant vaccinia viruses wherein a foreign gene is introduced by the present rescue system are confirmed to have expressed the foreign gene associated with the virus growth in the infected cells and acquired the character in accordance with the gene function.
The gene expressing a foreign gene prepared by the method of the present invention can be used for the treatment of various diseases.
All publications, patents, and patent applications cited in the present description are deemed to be incorporated herein per se by reference.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2016-138712 | Jul 2016 | JP | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/JP2017/025486 | 7/13/2017 | WO | 00 |
